Table 1.
Secretory protein-based pharmacological agents under development for treatment of nonalcoholic fatty liver disease (NAFLD)/NASH.
| Drugs | Target of Action | Company | Highest Developmental Stage |
|---|---|---|---|
| Liraglutide | GLP-1 receptor agonist | Novo Nordisk | Phase 2 |
| Semaglutide | GLP-1 receptor agonist | Novo Nordisk | Phase 2 |
| Cotadutide/MEDI0382 | GLP-1/GCG receptor dual agonist |
AstraZeneca/MEDIMMUNE | Phase 2 |
| CT-868 | GLP-1/GIP receptor dual agonist |
Carmot Therapeutics | Phase 1 |
| Trizepatide/LY3298176 | GLP-1/GIP receptor dual agonist |
Eli Lilly | Phase 2 |
| HM15211 | GLP-1/GCG/GIP receptor triple agonist | Hanmi Pharmaceutical | Phase 1 |
| Aldafermin (NGM282) | FGF19 analog | NGM Biopharmaceuticals | Phase 2b |
| Pegbelfermin (BMS-986036) |
FGF21 analog (PEGylated FGF21) |
Bristol-Myers Squibb/ Ambrx |
Phase 2b |
| AKR-001 | Fc-FGF21 | Akero | Phase 2 |
| BIO89-100 | FGF21 analog (glycoPEGylated FGF21) |
89bio | Phase 1b/2a |
| BFKB8488A | Agonistic anti-FGFR1/KLB antibody | Genentech, Inc. | Phase 1 |
| NGM313/ MK-3655 | Agonistic anti-FGFR1c/KLB antibody | Merck/ NGM Biopharmaceuticals |
Phase 1 |
| YH25724 | GLP-1/FGF21 dual agonist | Boehringer Ingelheim GmbH/Yuhan Corporation | Pre-clinical phase |
| CB4211 | MOTS-c analogs | CohBar, Inc. | Phase 1 |
| NGM395 * | GDF15 analogs | NGM Biopharmaceuticals | N/A (not applicable) |
| GDF15 Agonist ** | GDF15 analogs | Eli Lilly | N/A |
| LA GDF15 *** | GDF15 analogs | Novo nordisk | N/A |
* Phase 1 for obesity/NAFLD; ** phase 1 for type 2 diabetes; *** phase 1 for obesity.